 |
|
|
| |
Efficacy and safety of bepirovirsen in patients with chronic hepatitis B
virus infection: interim results from the randomised Phase 2b B-Clear study
|
| |
| |
EASL 2022 June 22-26 London
Presented by Professor Man-Fung Yuen on behalf of the B-Clear Study Group
Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
Bepirovirsen (GSK3228836) is an unconjugated antisense oligonucleotide targeting all HBV RNAs, including pregenomic RNA, via RNase H-mediated degradation resulting in reduction of viral proteins including HBsAg.6,7
|
| |
|
|
|
|
|
